There are currently 823 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ARrest RESpiraTory Failure From PNEUMONIA
NCT04193878
Recruiting
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Register for Updates
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of Florida, Jacksonville, Florida
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Register for Updates
Retina is a Marker for Cerebrovascular Heath
NCT04753970
Recruiting
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
Register for Updates
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
NCT05491525
Recruiting
The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/02/2024
Locations: Nemours Childrens Health, Jacksonville, Jacksonville, Florida
Conditions: Neurogenic Detrusor Overactivity
Register for Updates
Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
NCT05268250
Recruiting
This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
07/01/2024
Locations: Nemours Children's Health, Jacksonville, Florida
Conditions: Type 1 Diabetes
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Baptist MD Anderson Cancer Center, Jacksonville, Florida
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
NCT04830124
Recruiting
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Cutaneous Melanoma, Mucosal Melanoma
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Baptist MD Anderson Cancer Center, Jacksonville, Florida +2 locations
Conditions: Breast Cancer
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/20/2024
Locations: Wolfson Children's Hospital, Jacksonville, Florida
Conditions: Hydrocephalus
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Jacksonville, Florida
Conditions: Neoplasms
Register for Updates
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
NCT04040205
Recruiting
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or discontinuation criteria are met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
Register for Updates
Robotic-Assisted da Vinci System Prophylactic Nipple-Sparing Mastectomy
NCT03892980
Recruiting
This study evaluates the safety and effectiveness of the da Vinci Surgical Systems in prophylactic Nipple Sparing Mastectomy procedures.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
06/14/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Nipple Sparing Mastectomy
Register for Updates